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KEY POINTS
 The long-term treatment of Parkinson’s disease (PD) requires consideration regarding the
nature of dopaminergic treatment used to control motor symptoms, both in the early and
late stages of the illness.
 The concept of continuous dopaminergic stimulation has altered the face of treatment by
persuading clinicians that early use of a dopamine agonist can protect against the onset of
wearing off and dyskinesia.
 A mantra for treating PD is to adopt a philosophy of applying drug treatment as continu-
ously as possible, irrespective of whether the therapy is L-dopa or a dopamine agonist.
 Rotigotine delivered by a transdermal patch exemplifies continuous drug delivery, and its
ability to control wearing off and potentially avoid dyskinesia in patients with PD.
 Rotigotine supports the concept of delivering pharmacologic agents continuously in a
clear and concise manner that is relevant to not only clinical trials but also to the everyday
treatment of PD and to routine clinical practice.INTRODUCTION
The pharmacologic treatment of Parkinson’s disease (PD) is dominated by the use of
L-dopa (also known as levodopa) and dopamine agonists to control motor symptoms.1
Older ergot-related dopamine agonists such as bromocriptine and pergolide are no
longer in common use owing to safety concerns over pulmonary fibrosis and cardiac
valvulopathy,2 which do not occur with the nonergot derivatives ropinirole, pramipex-
ole, and rotigotine. The long-term use of dopamine replacement therapy demonstrated
that with disease progression, motor fluctuations, characterized by “wearing off” andFunding: None.
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JennerS18motor complications in the form of dyskinesia, become increasingly problematic in
maintaining symptomatic control.3 Both symptoms are more associated with the use
of L-dopa than with dopamine agonists; the basis of this concept is discussed in this
review. Although dyskinesia is considered a more significant event, wearing off affects
quality of life to a greater extent.4 These complications of therapy dictate the manner
whereby patients with PD are treated from diagnosis until the late stages of the illness.
The onset of either wearing off or dyskinesia commonly signals the risk of the appear-
ance of the other, but each does not necessarily occur in the same individual, and dif-
ferences in causative factors are not understood.5,6 Both occur more frequently with
the worsening of motor symptoms and with the extent and duration of drug treatment,3
which suggests that there is an opportunity to modify their onset and progression.
However, the pathophysiology of wearing off or dyskinesia is not fully understood,
and the most appropriate way of applying dopaminergic therapy remains debated.
This review looks at the current concepts underlying the genesis of both wearing off
and dyskinesia in PD, and suggests that using an approach to treatment based on
continuous drug delivery (CDD) may be a step forward in the control of these
symptoms.7WEARING OFF
Wearing off is defined as a gradual decrease in the duration of effect of each dose of
medication. It will eventually affect all patients with PD, but it is currently underrecog-
nized and is not considered an early event in the course of treatment.8 Nevertheless,
wearing off can appear within months or a few years of starting therapy, depending
on dose, as observed in a significant proportion of patients in studies of the early
use of L-dopa in PD (Earlier vs Later Levodopa Therapy in Parkinson’s Disease
[ELLDOPA] and Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease
[STRIDE-PD]).9,10 Sometimes neither physicians nor patients are aware that adjust-
ments to treatment regimens in early PD indicate the onset of wearing off and that
the signs are not limited to the return of motor symptoms, but can first become
apparent in relation to nonmotor symptomatology.8 Wearing off in patients with PD
is treated by alterations in the dosage or timing of L-dopa administration or by the addi-
tion of a longer-acting dopamine agonist; however, the manner whereby this is under-
taken may affect the outcome, as discussed later.
Because the pharmacokinetic profile of L-dopa does not change over the course of
PD or with the onset of wearing off, some centrally mediated pharmacodynamic
changes in L-dopa’s actions seem to be crucial.11 The concept of the cause of wearing
off is linked to the continuing degeneration of nigrostriatal dopaminergic neurons in the
progression of PD. This process is deemed to lead to reduced presynaptic handling
and storage of dopamine derived from L-dopa, and to a reduced buffering of striatal
dopamine receptors from the fluctuations in plasma concentrations of L-dopa that
occur over the course of the day.8 Certainly the duration of effect of a single dose
of L-dopa in patients with early PD exceeds that expected from the 90-minute plasma
half-life of the drug, which supports the storage concept. However, this explanation
may be simplistic, as wearing off can occur in response to dopamine-agonist treat-
ment whereby only postsynaptic responses are involved,12,13 although to a lesser
degree than with L-dopa. Similarly, in experimental models of PD where the majority
of dopaminergic neurons have been destroyed by the use of 6-hydroxydopamine
(6-OHDA) or 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), wearing off oc-
curred with repeated pharmacologic treatment.14 The nature of these postulated post-
synaptic changes is not known, and it is generally presumed that they involve striatal
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ment in motor symptoms in patients with PD. An alternative explanation lies in the dif-
ferences in pharmacology of L-dopa and dopamine agonists, with the former also
inducing D-1 receptor stimulation that may contribute to the improvement in motor
symptoms, which may explain the accepted greater efficacy of L-dopa compared
with D-2 selective dopamine agonists. This point may be important, because it is clear
that repeated stimulation of D-1 receptors leads to a rapid desensitization and toler-
ance to drug effects, perhaps induced by an internalization of receptors.15 The result
would be a decreased duration of drug response to L-dopa as occurs in wearing off in
PD patients, but this would not sufficiently explain why adding a dopamine agonist
“cures” wearing off.
One other component of the actions of dopaminergic drug action may also
contribute to the onset of wearing off: the complex issue of the short-duration and
long-duration response (SDR and LDR).16,17 The terms SDR and LDR are generally
used to describe the effects of L-dopa but can also apply to dopamine agonists.
SDR is the immediate effect of treatment seen after each dose of the drug, and fades
within a few hours. LDR is the effect of a drug that takes 2 to 3 weeks to become
established after treatment is initiated and then disappears slowly after stopping treat-
ment, with a return to a higher level of disability similar to that seen between doses
during treatment. Wearing off might immediately be thought to represent a shortening
of SDR but, perhaps surprisingly, it has been shown to involve a loss of LDR. However,
because the pathophysiologic basis of LDR is not understood,18 it is perhaps not help-
ful when considering the practical issues of controlling wearing off.DYSKINESIA
Dyskinesia is, in general, described as a single entity but actually comprises chorea,
dystonia, and athetosis that can be focal, segmental, or generalized.19 This distinction
serves to emphasize the complexity of the underlying pathophysiology that remains
poorly understood. Dyskinesia appears to be a postsynaptic phenomenon because
it does not usually occur in humans or animals with an intact nigrostriatal pathway.
Pharmacologic doses of L-dopa failed to produce dyskinesia in healthy animals
when administered on a chronic basis or in humans without PD who were treated
with L-dopa for many years.20,21 One exception is that large toxicologic doses of
L-dopa did induce dyskinesia in healthy primates,22 which suggests a role for drug
treatment (see later discussion).
By contrast, the administration of L-dopa to 6-OHDA–lesioned rats or in MPTP-
treated primates with greater than 90% loss of striatal dopaminergic input produced
involuntary movements very quickly, sometimes even after a single dose.23,24 Simi-
larly, in human studies the administration of L-dopa in MPTP-treated drug addicts,
individuals with previously untreated late stage PD, or those with young-onset PD
rapidly induced dyskinesia (and incidentally, wearing off), reflecting the underlying
severity of nigral dopaminergic cell loss.25–27 Indeed, there is little doubt that the pri-
mary predisposing factor for dyskinesia induction is the extent of nigral cell degener-
ation, which dictates the dose and duration of treatment with L-dopa required to
induce dyskinesia. A recent reanalysis of the STRIDE-PD study showed age, disease
severity, L-dopa dose, gender (female), body weight, and United States location as
significant factors in determining the prevalence of dyskinesia.
The appearance of dyskinesia in patients with PD has 2 major components: (1) a
priming process that lays down a motor memory for the expression of abnormal invol-
untary movements (AIMs), and (2) the expression of dyskinesia that then occurs in
JennerS20response to each dose of dopaminergic medication.28,29 Priming is the least
well-understood component, but its persistent, if not permanent, nature suggests
fundamental change in basal ganglia output; this may involve complex changes in
intracellular signaling and alterations in processes such as long-term potentiation
and long-term depression. Substantial evidence in the literature links dyskinesia to
D-1 receptor function, and is considered to be the reason why dyskinesia appears
more commonly with L-dopa than with D-2 selective dopamine agonists (see, eg,
Berthet and colleagues30). In turn, this implicates the direct striatal output pathway
and the involvement of the internal segment of the globus pallidus, as shown in classic
models of basal ganglia function. However, because these data come from experi-
mental models of PD (the AIMs model in 6-OHDA–lesioned rats and the dyskinetic
MPTP-treated primate), its relevance to humans is uncertain, and it is difficult to sepa-
rate the changes caused by L-dopa treatment from those treatments that induce
dyskinesia. The same emphasis has not been applied to intracellular signaling events
related to D-2 receptor function to determine the role it might play, and hence the
involvement of the indirect output pathway in the external segment of the globus pal-
lidus and, in turn, the subthalamic nucleus. Indeed, once dyskinesia is established,
both D-1 and D-2 receptor agonists are capable of inducing the same involuntary
movements, although the intensity may be different.31
It is obvious that the explanations for the occurrence of wearing off and dyskinesia
sound very similar, which reflects the current uncertainty regarding their pathogenic
mechanisms. At best, wearing off might be seen as more presynaptic than postsyn-
aptic, whereas dyskinesia is more postsynaptic than presynaptic. With respect to
postsynaptic events, different signaling pathways are responsible for the expression
of wearing off and dyskinesia, as similar (if not identical) causative factors are
invoked. Simplistically, there may be differences in the D-1–mediated indirect output
pathway and D-2–mediated direct output pathway, but the reality is that nobody
knows.PHARMACOLOGIC TREATMENT AND DYSKINESIA
In addition to the extent of nigral cell degeneration, the nature of pharmacologic treat-
ment has a significant effect on the emergence of dyskinesia. It appears that using oral
dopamine-agonist therapy in patients with early PD is less likely to induce dyskinesia
than would occur with L-dopa. A lower prevalence of dyskinesia or rate of emergence
has occurred in early oral dopamine-agonist monotherapy studies using ropinirole,
pramipexole, pergolide, or cabergoline in comparison with L-dopa treatment.32–36
However, overall dopamine agonists did not produce the same level of improvement
in the Unified Parkinson Disease Rating Scale (UPDRS) scores as seen with L-dopa,
and it is not known what would have happened in relation to dyskinesia had clinical
efficacy been equal. This initial benefit on prevalence of dyskinesia can be lost in those
patients requiring L-dopa supplementation in whom, over time and with disease pro-
gression, the differentiation between oral dopamine agonists and L-dopa can become
blurred.6 Three other points are worthy of note. First, results from the agonist mono-
therapy studies ELLDOPA and STRIDE-PD indicated that dyskinesia can occur early
in the course of L-dopa treatment. Second, although L-dopa induced a higher preva-
lence of dyskinesia, most occurrences were mild and nontroublesome, with no differ-
ence in troublesome symptoms in comparison with dopamine agonists, although
these were uncommon. This finding reflects the lower degree of nigral cell loss in
early-stage PD. Third, in STRIDE-PD, there was a dose relationship to the incidence
of dyskinesia, such that at doses less than 400 mg/d the incidence of dyskinesia
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nesia in the comparison of immediate-release (IR) L-dopa (Sinemet) with continuous-
release (CR) L-dopa (Sinemet CR), both in combination with carbidopa, reported in the
CR Five-Year International Response Fluctuation (CR First) trial.37CONTINUOUS DOPAMINERGIC STIMULATION AND ITS FLAWS
The explanation for the lower incidence of dyskinesia and wearing off associated with
the use of dopamine agonists led to the concept of continuous dopaminergic stimula-
tion (CDS), which has been the rationale for treatment with dopamine agonists in the
early treatment of PD.38 In brief, CDS is underpinned by data showing that tonic firing
of dopaminergic neurons results in a steady baseline concentration of extracellular
dopamine in the striatum, independent of movement. Coupled with high-frequency
burst firing in response to movement and the presynaptic buffering of dopamine
afforded vesicular storage, this translates into continuous stimulation of postsynaptic
dopamine receptors. Consequently, the loss of the buffering capacity in PD as presyn-
aptic terminals degenerate leads to nonphysiologic stimulation of dopamine receptors
and subsequently to abnormalities of striatal function. For example, in 6-OHDA–
lesioned rats, administration of L-dopa resulted in far more marked increases in extra-
cellular dopamine levels than those seen in healthy rats, as its uptake and storage in
dopaminergic terminals had been lost.39 On repeated L-dopa treatment, extracellular
dopamine levels in those 6-OHDA–lesioned rats that developed AIMs were approxi-
mately twice those reported in animals not showing involuntary movements.40 This
finding is reflected in humans through the higher striatal synaptic dopamine levels
observed in L-dopa–treated patients with PD who exhibited wearing off and dyskinesia
when compared with stable responders, as assessed by positron emission tomogra-
phy (PET).41 The application of this knowledge to the lower incidence of motor fluctu-
ations and complications produced by dopamine agonists led to the clinical
application of CDS.
The plasma half-lives of the 2 treatments are a clear differentiator between oral
L-dopa and oral dopamine-agonist administration used in the early agonist monother-
apy studies.34 At a basic level, the short duration of effect of IR L-dopa was related to
its rapid clearance from plasma (with a half-life of w90 minutes), which resulted in a
pulsatile nonphysiologic stimulation of striatal dopamine receptors in PD patients.
This process was postulated to cause alterations in molecular signaling and genetic
changes in basal ganglia, resulting in dyskinesia. By contrast, the more prolonged
duration of effect of dopamine agonists linked to their considerably longer presence
in plasma was taken as evidence that they could provide a more continuous physio-
logic dopaminergic stimulation, which resulted in less perturbation of striatal function
and less dyskinesia. Indeed, in studies in MPTP-treated primates, a range of
dopamine-agonist drugs was shown to induce fewer occurrences of dyskinesia
than seen with equivalent doses of L-dopa.42–44 So far, so good.
However, there is no correlation between the half-lives of the dopamine agonists
administered in patients with PD and the prevalence of dyskinesia in monotherapy
studies.34 Cabergoline has the longest plasma half-life but produces the highest
incidence of dyskinesia. Commonly used dopamine agonists such as the immediate
release formulations of ropinirole and pramipexole are dosed 3 times daily and are
not effective over the nighttime period, so they clearly do not result in CDS. The
extended-release (ER) compounds of pramipexole and ropinirole taken in the morn-
ing produce more stable plasma drug levels over the daytime period45 but, in gen-
eral, do not control nocturnal symptoms.
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mine agonists of differing half-lives or duration of effect that test the validity of CDS.
All studies to date have involved comparisons between L-dopa and a dopamine
agonist, which may be misleading. In the MPTP-treated primates, where more dopa-
mine agonists have been investigated for the induction of dyskinesia than in humans,
no correlation was found between duration of drug effect and dyskinesia induction;
however, few head-to-head studies have been conducted.7,46 In a comparison of
dyskinesia induction in MPTP-treated common marmosets treated with the short-
acting dopamine agonist apomorphine and the long-acting dopamine agonist pergo-
lide versus L-dopa, which has an intermediate duration of effect, both dopamine
agonists produced fewer cases of involuntary movements.42 Another comparison of
subcutaneous administration of the dopamine agonist rotigotine, which is shorter
acting than oral L-dopa (see later discussion), in a dose that improved motor function
to the same degree as L-dopa, resulted in far lower incidences of dyskinesia.47 In the
6-OHDA–lesioned rat, however, a better correlation with duration of effect seemed to
occur in both induction and expression of AIMs.48 Plasma half-lives of drugs may not
be the best guide to whether CDS is achieved. The partial dopamine agonist pardo-
prunox has a plasma half-life of 2 to 3 hours, but PET studies have shown that its
half-life at striatal dopamine receptors is 11 to 13 hours.
The foregoing discussion suggests that CDS may not explain why differences exist
between L-dopa and dopamine agonists for dyskinesia induction. In fact, the differ-
ences in dyskinesia induction between L-dopa and dopamine agonists may be more
related to pharmacology than to pharmacodynamics or pharmacokinetics. Dopamine
agonists such as ropinirole and pramipexole act selectively on D-2/D-3 receptors
(D-2–like receptors), and are therefore limited in their pharmacologic effects because
5 dopamine receptor subtypes (D-1–like and D-2–like receptors) exist.49 By contrast,
L-dopa forms dopamine that interacts with both D-1–like and D-2–like dopamine re-
ceptors as well as affecting noradrenergic, serotoninergic, and glutamatergic function.
Because D-1–like receptors have been implicated in both the reversal of motor deficits
and dyskinesia induction in PD patients, it seems feasible that L-dopa has a higher
efficacy and greater ability to induce dyskinesia because of its broader pharma-
cology.45,46 Indeed, L-dopa and dopamine agonists should not be considered as
equivalent drugs but rather representatives of 2 distinct drug classes. There may
also be differences in dyskinesia expression related to the pharmacology of dopamine
agonists in comparison with L-dopa. Thus, whereas administration of dopamine
agonists ropinirole and piribedil to MPTP-treated primates resulted in only a low level
of dyskinesia, switching to an equivalent dose of L-dopa immediately invoked intense
dyskinetic movements.50,51 By contrast, switching from L-dopa to an equivalent dose
of a dopamine agonist immediately reduced dyskinesia intensity. This finding sug-
gests that dopamine agonists do prime for dyskinesia but do not lead to its expres-
sion, whereas L-dopa results in priming and expression, which may ultimately be
related to its D-1 receptor activity.
It is interesting that combinations of dopamine agonists and L-dopa have effects
dependent on the proportionality of effect. A comparison of pramipexole and L-dopa
for dyskinesia induction in MPTP-treated primates showed, as expected, that the
dopamine agonist produced far fewer involuntary movements than L-dopa.52 How-
ever, switching the L-dopa–treated animals to a combination of pramipexole with a
halved dose of L-dopa maintained the improvement in motor function, but produced
no more occurrences of dyskinesia expression when compared with pramipexole
alone. These results had been reported in MPTP-treated primates treated with ropini-
role plus L-dopa, where an agonist-dominant combination resulted in low levels of
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movements.53MOVING TO CONTINUOUS DRUG DELIVERY
CDS fails to explain differences between L-dopa and dopamine agonists and also fails
to explain differences between dopamine agonists of different plasma half-lives, at
least in MPTP-treated primates and humans. The validity of CDS requires a belief in
the exact nature of changes in striatal dopamine receptors and in basal ganglia output
at the cellular and molecular level that leads to the genesis and expression of dyski-
nesia. To date this is not a certainty, and brings a level of complexity to the application
of CDS that is far removed from clinical practice. However, one aspect of CDS may be
correct, and may form an easily applicable clinical tenet: namely, the delivery of drugs
in PD is important, irrespective of whether it is L-dopa or dopamine agonists, and that
CDD is the key to successful treatment. This tenet was the original intention of the
concept of CDS, which was based on the use of intravenous and subcutaneous infu-
sions of L-dopa and lisuride in treating PD,54 but was then appropriated to describe
events occurring with oral administration of dopamine agonists. Subsequently, the
importance of CDD has been demonstrated in studies using both 6-OHDA–lesioned
rats and MPTP-treated primates, and in humans.7,46,55
The repeated oral administration of L-dopa to 6-OHDA rats leads to shortening of
drug response, sharpening of peak effects, sensitization to dopamine agonists, induc-
tion of AIMs, and molecular and receptor changes associated with wearing off and
dyskinesia induction.14,56 The delivery of L-dopa from an intraperitoneal mini-pump
avoided sensitization to the effects of apomorphine, suggesting that changes in
drug delivery may have beneficial effects. This result appears to be in line with the abil-
ity of continuous intravenous and intraduodenal infusion of L-dopa to control wearing
off in PD patients, while intraduodenal infusion has also been reported to diminish
established dyskinesia over time.57 Similarly, combining L-dopa with the catechol-
O-methyltransferase inhibitor entacapone in 6-OHDA–lesioned rats was shown to
delay wearing off, decrease AIM induction, and prevent molecular changes in striatum
associated with both dyskinesia and wearing off.58–60 In MPTP-treated primates, a
combination of L-dopa and entacapone administered 4 times daily reduced dyskinesia
induction alone and in combination with a dopamine agonist, suggesting altered
delivery of L-dopa–affected outcome.61,62 However, this did not translate into a clini-
cally relevant effect when applied in STRIDE-PD in early L-dopa treatment of PD that
compared L-dopa/carbidopa with L-dopa/carbidopa/entacapone, or in the earlier CR
First study comparing L-dopa/carbidopa IR (Sinemet) with CR (Sinemet CR), where an
equivalent prevalence of dyskinesia occurred.10,37 Indeed, in a recent study of
6-OHDA–lesioned rats, another fly appears in this particular ointment. A comparison
of intraperitoneal bolus administration of L-dopa with 8-hour daily intraduodenal infu-
sions found no difference in the rate of induction or intensity of AIMs, although infusion
of L-dopa appeared to reduce the duration of established AIM expression over each
treatment day.63 This result again suggests that there is something intrinsic to
L-dopa that underlies its ability to induce dyskinesia.
The role of CDD in the effects of dopamine agonists in PD seems clearer. In MPTP-
treated monkeys the highly selective D-2 receptor agonist, U-91356A, administered
by repeated subcutaneous injection, reversed motor deficits but resulted in progres-
sive dyskinesia.64 By contrast, continuous infusion with an osmotic mini-pump
implanted subcutaneously resulted in only mild transient dyskinesia. Similarly,
although repeated daily subcutaneous administration of apomorphine to
JennerS24MPTP-treated primates induced dyskinesia within 2 weeks, continuous delivery of
the drug from a subcutaneously implanted slow-release polymer rod system did
not produce dyskinesia, even after 6 months.65 In addition, low levels of dyskinesia
seen following repeated oral treatment with ropinirole were reduced even further by
the continuous infusion of the drug.66 These data emphasize the advantages that
CDD can provide and its ease of application in the treatment of patients with PD,
and reflects the results obtained using both subcutaneous infusion of apomorphine
and intraduodenal infusion of L-dopa in patients with motor fluctuations and motor
complications.67 However, both are invasive technologies and are therefore limited
to specific patient populations.ROTIGOTINE, AN ARCHETYPAL APPROACH TO APPLYING CDD IN THE CLINIC
CDD in patients with PD can be achieved through the use of subcutaneous infusion of
apomorphine or the intraduodenal administration of L-dopa, although, as previously
stated, this can be invasive and technically challenging.46 CDD is not achieved by
the routine use of ER forms of oral dopamine agonists or CR oral L-dopa. It is achieved,
however, with the continuous 24-hour delivery of rotigotine using a transdermal patch,
which consequently is used here to illustrate the concept of CDD and its application to
clinical use in PD.
Rotigotine is a D-3>D-2>D-1 dopamine agonist that exerts interesting functional
interactions with 5-HT1A and a-2B adrenergic receptors (Table 1).
68 Rotigotine was
originally considered as a development candidate for oral administration in patients
with PD. However, while effective in reversing motor deficits in 6-OHDA–lesioned rats
and MPTP-treated primates (Table 2),69–73 its duration of action was short74 although
it correlated with plasma drug levels.75 Of importance, rotigotine was shown to be
effective after application to the skin in both 6-OHDA–lesioned rats and MPTP-
treated primates, producing effects on motor disability that lasted 48 to 72 hours
in comparison with 90 minutes after oral administration (see Table 2).71,76Table 1
Rotigotine receptor binding profile
Receptor Ki (nM)
Dopaminergic
D1 83
D2 17
D3 0.71
D4 15
D5 6.3
Serotonergic
5-HT1A 30
5-HT1D 853
5-HT7 86
Adrenergic
a-2A 338
a-2B 27
a-2C 135
Data from Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new
agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol
2009;379(1):73–86.
Table 2
Effects of rotigotine in animal models of PD
Preparation Result of Rotigotine Treatment
6-OHDA–lesioned rat69,73,76,81
Acute treatment Dose-dependent contralateral rotation
Repeated treatment No sensitization or tolerance; few AIMs
Continuous treatment Contraversive rotations; no observed AIMs
MPTP-treated primate47,71
Acute treatment Increased locomotor activity
Reversed motor disability
Repeated treatment Increased locomotor activity
Reversed motor disability
Low-intensity dyskinesia
Striatal microdialysis/slice72,76–79
Acute treatment Dose-dependent decrease in striatal dopamine release
Decrease in striatal dopamine metabolites also observed
Continuous treatment Dopamine levels decreased to 20% of control over 48 h
Abbreviations: 6-OHDA, 6-hydroxydopamine; AIMs, abnormal involuntary movements; MPTP,
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
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dopamine levels73,77,78 and that the continuous delivery of the drug resulted in con-
stant levels in the striatum which, importantly, resulted in a continuous activation of
dopamine receptors (see Table 2).79 From this starting point, technology was devel-
oped for its transdermal delivery in PD patients resulting in constant plasma levels
over 24 hours.80
In subsequent studies, the potential advantages of the continuous delivery of roti-
gotine for the treatment of wearing off and dyskinesia in patients with PD became
evident (see next section). In 6-OHDA–lesioned rats, the continuous delivery of rotigo-
tine using an injected slow-release formulation generating sustained plasma levels did
not induce the sensitization to drug effect that had been reported with repeated short-
acting subcutaneous injection of the drug or with oral L-dopa administration (see
Table 2).81 Of note, the continuous delivery of rotigotine did not induce AIMs in
rats and altered the pattern of gene change in comparison with both repeated subcu-
taneous injection of rotigotine and repeated L-dopa treatment.82 Similar effects have
been seen in 6-OHDA–lesioned rats treated with rotigotine-loaded microspheres.83 In
MPTP-treated primates, the repeated subcutaneous injection of short-acting rotigo-
tine induced a lower intensity of dyskinesia than repeated treatment with L-dopa,
as expected for a dopamine agonist, and both agents reversed motor disability.47
However, continuous delivery of rotigotine induced even less dyskinesia than seen
on repeated injection, and prolonged the duration of reversal of motor deficits.
Once dyskinesia had become established, switching from oral L-dopa treatment or
repeated short-acting injections of rotigotine to continuous delivery decreased the
intensity of dyskinesia.84 Conversely, halting continuous delivery of rotigotine and
introducing short-acting L-dopa or rotigotine injection enhanced or reintroduced
marked involuntary movements. These data illustrate that rotigotine has the advan-
tages of using a dopamine agonist, the ability to minimize the intensity of dyskinesia,
and the convenience and effectiveness of applying the CDD approach to treatment
that maximizes the duration of response and minimizes the risk of perturbations in
striatal function.
Table 3
Clinical studies of rotigotine
Study
No. of Sites/Geographic
Location(s) Study Design
Study
Duration Primary Efficacy Variables
Secondary Efficacy
Variables
Early PD
Parkinson’s Study
Group,91 2003
36 sites
USA and Canada
Randomized, multicenter,
double-blind,
placebo-controlled,
parallel-group,
dose-ranging
14 wk Change in UPDRS II and III
sum score (BL to EoM)
Change in UPDRS I, II, and
III subscores
Change in Hoehn and Yahr
stage
End of treatment
responder rates
Watts et al,95
2007
50 sites
USA and Canada
Randomized, double-blind,
placebo-controlled
24 wk Change in UPDRS II and III
sum score
UPDRS (II1III) responders
Percent change in UPDRS
II and III
Change in UPDRS II
Change in UPDRS III
CGI
Hoehn and Yahr stage
Giladi et al,90
2007
NA
Multinational
Randomized, multicenter,
double-blind, placebo- and
ropinirole-controlled,
parallel-group, dose-
ranging
45 wk Proportion treatment
responders
Percent change in UPDRS
II and III
Change in UPDRS II
Change in UPDRS III
Elmer et al,110
2012
43 sites
USA and Canada
Open-label continuation 6 y UPDRS II, III, and IV
UPDRS II and III responders
Motor/dyskinesia assessment
CGI
Hoehn and Yahr stage
Time to adjunctive L-dopa
therapy
Monotherapy status at
end of open-label
treatment
Je
n
n
e
r
S
2
6
Advanced stage PD
Babic et al,108
2006
5 sites
UK, Czech Republic,
Croatia
Open-label, randomized,
parallel group,
multicenter, dose
escalation
18 wk Safety and tolerability
LeWitt et al,99
2007
54 sites
USA and Canada
Randomized, double-blind,
placebo-controlled,
parallel group
24 wk Reduction in absolute time
spent off (BL to EoM)
Patient response
Change, % change in
absolute and relative on
and off time, and on
with/without dyskinesia
No. of off periods
On/off status at waking
Change in UPDRS II, III, or IV
during on time
AUC: absolute time off
Clinical pharmacology
Poewe et al,101
2007
77 sites
EU, South Africa, Australia,
New Zealand
Randomized, double-blind,
double-dummy,
placebo- and
pramipexole-controlled,
parallel-group
32 wk Change in absolute time
spent off (BL to EoM)
Patient response (30%
reduction absolute off
time)
Change, absolute and
relative, in on and off
time, number of off
periods, on/off status
at waking
Change in UPDRS II, III, or IV
during on time
AUC: absolute time off
PDSS
Other clinical studies
Trenkwalder
et al,107 2011
49 sites
UK, USA, Africa, Australia,
EU, New Zealand
Randomized, double-blind,
placebo-controlled,
parallel group,
multicenter, multinational
22 wk UPDRS III (early morning)
PDSS-2 total
PDSS-2 items
NADCS
Nocturia
Abbreviations: AUC, area under the curve; BL, baseline; CGI, Clinical Global Impression; EoM, end of maintenance; EU, European Union; NA, not available; NADCS,
Nocturnal Akinesia, Dystonia, and Cramps Score; PDSS, Parkinson Disease Sleep Scale; UPDRS, Unified Parkinson Disease Rating Scale.
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JennerS28ROTIGOTINE IN CLINICAL USE IN PD
Rotigotine has been available in Europe for several years, having received favorable
acceptance for its convenience, ease of use, and efficacy in controlling motor symp-
toms of PD.85–88 In clinical trials, the once-daily application of the rotigotine trans-
dermal patch (Neupro) produced dose-related improvements in UPDRS (parts II and
III) combined scores, with rapid upward dose titration and allowance for L-dopa
dose reduction, and was safe and well tolerated in both the short and long term
(Table 3).89–95 Moreover, the once-daily regimen led to a high degree of compliance.96
In routine clinical practice, the use of the rotigotine patch has allowed some reduction
in other PD medications, improved sleep quality, and reduced nocturia.97
In later-stage PD in patients exhibiting motor fluctuations and motor complications,
the introduction of continuous delivery of rotigotine resulted in a significant dose-
related reduction in “off time” while allowing a reduction in L-dopa dosage without
any loss of control of motor symptoms and effects similar to those of pramipexole
treatment.98–102 This finding is consistent with the concept that CDD is effective in
controlling the motor fluctuations of wearing off. “On time” without dyskinesia
increased in most patients but did not reach statistical significance. Similarly, on
time after awakening without dyskinesia more than doubled after the introduction
of rotigotine, and an improvement in early-morning akinesia was observed.103 In
short, improvements in sleep and motor function on awakening resulting from CDD
were achieved with the rotigotine transdermal system.104–107 These improvements
in off time, sleep, and quality of life demonstrate the advantages of CDD through
the nighttime period. Moreover, a more rapid escalation of dose did not produce
an increase in adverse events than those seen with a slower incremental rate,108
and switching from oral dopamine-agonist therapy to rotigotine patch treatment
was easy and effective.109
In the treatment of early PD, the potential of CDD for avoiding dyskinesia in-
duction has been observed. Use of the rotigotine patch markedly improved motor
function and diminished the need for L-dopa, in terms of both the number of pa-
tients requiring treatment compared with the placebo-treated group and the
dosage used.98,110 The majority of studies were too short to merit comment on
dyskinesia induction, but in long-term (up to 6 years) open-label extension studies,
the efficacy of rotigotine was maintained, with an incidence of dyskinesia of 25%
and with involuntary movements most commonly occurring after the introduction
of L-dopa.110
SUMMARY
The long-term treatment of PD requires consideration regarding the nature of dopa-
minergic treatment used to control motor symptoms, in both the early and late stages
of the illness. The concept of CDS has altered the face of treatment by persuading
clinicians that early use of a dopamine agonist can protect against the onset of wear-
ing off and dyskinesia. However, CDS does not explain many of the preclinical and
clinical observations made in relation to the effects of L-dopa and dopamine agonists,
and also requires an understanding of the complexities of events occurring at the
cellular and molecular level in the striatum, which are themselves uncertain. Rather,
an easier mantra for treating PD is to adopt a philosophy of applying drug treatment
as continuously as possible, irrespective of whether the therapy is L-dopa or a dopa-
mine agonist. This rule is simple to apply, and reflects what was understood by the
original definition of CDS in relation to infusions of L-dopa, apomorphine, and lisuride.
Rotigotine delivered by a transdermal patch exemplifies CDD and its ability to control
Continuous Drug Delivery in Parkinson Disease S29wearing off and potentially avoid dyskinesia in patients with PD. It also supports the
concept of delivering pharmacologic agents continuously in a clear and concise
manner that is relevant not only to clinical trials but also to the everyday treatment
of PD and to routine clinical practice.REFERENCES
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